GlassScriptPhysician profile
Brenda Blickhan
NPI 1063000719
$1,440.13
in general payments reported to CMS, 2019-2025
20 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2024: $542 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.95 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $280.74 | 2024 | Pemazyre, Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $245.41 | 2024-2025 | Imfinzi, Calquence |
| Daiichi Sankyo INC. | $220.83 | 2024-2025 | Enhertu, Datroway |
| Boston Scientific Corporation | $105.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $91.83 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $80.96 | 2024-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $71.30 | 2024-2025 | Opdivo |
| Janssen Biotech, INC. | $59.31 | 2025 | Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $52.66 | 2025 | |
| Glaxosmithkline, LLC. | $28.54 | 2025 | Blenrep, Ojjaara |
| Genmab U.S., INC. | $27.62 | 2025 | |
| Coherus Oncology, INC. | $25.35 | 2024 | |
| Myriad Genetic Laboratories, INC. | $23.46 | 2024 | Myrisk |
| Eisai INC. | $20.12 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.91 | 2025 | Monoferric |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.25 | 2025 | Trodelvy |
| Celgene Corporation | $19.03 | 2024 | Reblozyl |
| Lilly USA, LLC | $18.83 | 2024 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2025 | Libtayo |
| Therapeuticsmd, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Blickhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.